Clinical Utility of the 12-Gene DCIS Score Assay: Impact on Radiotherapy Recommendations for Patients with Ductal Carcinoma In Situ.

MLA

Manders, Jennifer B., et al. “Clinical Utility of the 12-Gene DCIS Score Assay: Impact on Radiotherapy Recommendations for Patients with Ductal Carcinoma In Situ.” Annals of Surgical Oncology, vol. 24, no. 3, Mar. 2017, pp. 660–68. EBSCOhost, https://doi.org/10.1245/s10434-016-5583-7.

APA

Manders, J. B., Kuerer, H. M., Smith, B. D., McCluskey, C., Farrar, W. B., Frazier, T. G., Li, L., Leonard, C. E., Carter, D. L., Chawla, S., Medeiros, L. E., Guenther, J. M., Castellini, L. E., Buchholz, D. J., Mamounas, E. P., Wapnir, I. L., Horst, K. C., Chagpar, A., Evans, S. B., … White, J. (2017). Clinical Utility of the 12-Gene DCIS Score Assay: Impact on Radiotherapy Recommendations for Patients with Ductal Carcinoma In Situ. Annals of Surgical Oncology, 24(3), 660–668. https://doi.org/10.1245/s10434-016-5583-7

Chicago

Manders, Jennifer B, Henry M Kuerer, Benjamin D Smith, Cornelia McCluskey, William B Farrar, Thomas G Frazier, Linna Li, et al. 2017. “Clinical Utility of the 12-Gene DCIS Score Assay: Impact on Radiotherapy Recommendations for Patients with Ductal Carcinoma In Situ.” Annals of Surgical Oncology 24 (3): 660–68. doi:10.1245/s10434-016-5583-7.